Cao Xiangyu, Wang Jun, Tian Chenglin, Du Zhihua, Su Hui, Liu Xinfeng, Lv Bin, Yu Shengyuan, Chen Xing, Hui Ferdinand
Department of Neurology, Chinese PLA General Hospital, Beijing, China.
Beijing Advanced Innovation Center for Biomedical Engineering, Beihang University, Beijing, China.
Interv Neuroradiol. 2020 Oct;26(5):608-614. doi: 10.1177/1591019920951651. Epub 2020 Aug 25.
Vascular angioplasty and stenting of middle cerebral artery (MCA) and basilar artery (BA) stenoses are associated with poor clinical outcomes and high mortality rates thought to be related to the abundance of perforating arteries in those segments. This study explores the use of Solitaire AB as an off-label vascular stent to treat stenoses in the MCA and BA.
Solitaire AB stents were placed during angioplasty and stenting of MCA and BA stenoses in patients at our department between January 2015 and May 2017 with 6-36 months follow-up. Operative results were assessed by follow-up angiography and transcranial doppler after the procedure. Neurologic status was evaluated before and after treatment according to the modified Ranking Scale (mRS).
A total of 32 patients were included in the study. Seventeen (53.12%) patients presented with MCA stenosis and 15 (46.87%) with BA stenosis. The 30-day rate of procedure-related complications was 3.1% (1/32). Post-stenting residual stenosis degrees ranged from 0% to 40% (mean 13.44% ± 10.66%). Mean degree of residual stenosis in 26 patients followed up by DSA was 8.64% ± 9.67%. The mRS 0-2 was achieved in all (100%) patients at 6-12 months post-procedure.
Our study indicates the off-label use of Solitaire AB for stenting is effective and safe for MCA and BA stenoses with high technical success and low complications. We recommend that lesion-specific therapy with an anatomically fitted stent design enables optimal treatment for intracranial stenosis.
大脑中动脉(MCA)和基底动脉(BA)狭窄的血管成形术和支架置入术与不良临床结局及高死亡率相关,这被认为与这些节段丰富的穿支动脉有关。本研究探讨使用Solitaire AB作为一种非标签血管支架来治疗MCA和BA狭窄。
2015年1月至2017年5月期间,在我院对患有MCA和BA狭窄的患者进行血管成形术和支架置入术时放置Solitaire AB支架,并进行6至36个月的随访。术后通过随访血管造影和经颅多普勒评估手术结果。根据改良Rankin量表(mRS)在治疗前后评估神经功能状态。
本研究共纳入32例患者。17例(53.12%)患者表现为MCA狭窄,15例(46.87%)表现为BA狭窄。与手术相关的并发症30天发生率为3.1%(1/32)。支架置入术后残余狭窄程度范围为0%至40%(平均13.44%±10.66%)。通过数字减影血管造影(DSA)随访的26例患者残余狭窄平均程度为8.64%±9.67%。术后6至12个月时所有患者(100%)均达到mRS 0 - 2级。
我们的研究表明,Solitaire AB支架非标签用于MCA和BA狭窄的支架置入术是有效且安全的,技术成功率高且并发症少。我们建议采用解剖学适配的支架设计进行病变特异性治疗能够为颅内狭窄提供最佳治疗。